Susan Wingo
Endocrinology, Diabetes & Metabolism · Amarillo, TXNPI 1457397697
Payments from drug & device makers
Across 332 payments — averaging $19.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Novo Nordisk$874
- Lilly USA, LLC$780
- Boehringer Ingelheim$439
- Dexcom, Inc.$366
- Amgen$356
- plus $2K from 20 others
What the payments were for
- Travel & lodging$1,13818%
- Food & beverage$5,08779%
- Education$1212%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 19 | $1,328 |
| Novo Nordisk | 65 | $874 |
| Lilly USA, LLC | 52 | $780 |
| Boehringer Ingelheim | 30 | $439 |
| Dexcom, Inc. | 23 | $366 |
| Amgen(2 entities) | 13 | $356 |
| Abbott | 16 | $322 |
| Corcept Therapeutics | 18 | $313 |
| Sanofi-aventis U.S. LLC | 18 | $261 |
| Recordati_rare_diseases_inc. | 5 | $196 |
| AstraZeneca(2 entities) | 13 | $180 |
| Xeris Pharmaceuticals, Inc. | 8 | $142 |
| Merck | 10 | $130 |
| Amryt Pharma Holdings Ltd | 6 | $124 |
| Radius Health, Inc. | 7 | $91 |
| Mannkind Corporation | 3 | $88 |
| Amarin Pharma, Inc. | 4 | $67 |
| AbbVie | 4 | $56 |
| Pfizer | 3 | $54 |
| Insulet Corporation | 3 | $53 |
| Bayer | 3 | $53 |
| Johnson & Johnson | 4 | $50 |
| EUSA Pharma (US) LLC | 2 | $24 |
| IBSA Pharma Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $20 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Minimed 670G System$1,009
How this compares
$6,405 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 53 | $74,621 |
| TrulicityDulaglutide | 16 | $20,836 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $9,807 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $8,738 |
| Levothyroxine Sodium | 99 | $978 |
| Metformin Hcl ErMetformin Hcl | 33 | $220 |
| Gabapentin | 19 | $179 |
| Glimepiride | 14 | $174 |
| Glipizide | 12 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $874 | $74,62153 claims |
| Lilly USA, LLCTrulicity | $780 | $20,83616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Amarillo
- William BiggsAmarillo$2.2M
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.